MannKind | MNKD - Capitale Ordinario





Capitale Ordinario Cambiamento Data
Adma Biologics USD 232.29M 5.59M 2026-03
BioCryst Pharmaceuticals USD 255.26M 42.2M 2026-06
Eli Lilly USD 943.5M 3.33M 2026-03
Halozyme Therapeutics USD 114.04M 4.48M 2026-06
Insmed USD 218.28M 1.76M 2026-06
Karyopharm Therapeutics USD 22.54M 4.23M 2026-03
MacroGenics USD 63.56M 241K 2026-03
MannKind USD 309.91M 1M 2026-06
Merck USD 2.47B 4.93M 2026-03
Minerva Neurosciences USD 1000 0 2024-09
Novavax USD 162.58M 106K 2025-12
Novo Nordisk DKK 4.43B 13.25M 2026-06
Pfizer USD 5.7B 0 2026-06
Sanofi EUR 1.21B 8.25M 2026-03
Xencor USD 74.33M 265K 2026-06